AVAILABLE MEDICINE FOR Ceritinib

There are no products to list.

Introduction to Ceritinib

Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor used in the treatment of non-small cell lung cancer (NSCLC). Ceritinib is a targeted cancer therapy drug belonging to the class of tyrosine kinase inhibitors. It was approved for its medical use on 29th April 2014. 

How it Works:

Ceritinib inhibits the activity of the ALK mutation, a genetic alteration that drives cancer cell growth in certain types of NSCLC.

Uses:

Treatment of ALK-positive metastatic NSCLC.

Side Effects:

• Nausea, diarrhea
• elevated liver enzymes.
• Rare: lung toxicity
• QT prolongation.